Compound class:
Synthetic organic
Comment: Neoceptin-3 is a synthetic molecular Toll-like receptor 4 (TLR4) agonist mimetic [2]. It bears no structural similarity with the endogenous ligand for TLR4, LPS, and in fact the biologically relevant molecular target for neoseptin-3 is the TLR4/MD-2 (LY96) complex [3]. This is one of the compounds claimed in patent WO2014131023 [1] in which the compound's action as an immune system adjuvant is claimed. Neoceptin-3 is claimed for its ability to elicit an immune response via TLR4, without the toxicity exhibited by LPS [3]. The S stereoisomer is specified in [3]. The R stereoisomer is represented by PubChem CID 90371379.
|
|
References |
1. Beutler B, Boger DL. (2014)
Neoseptins: small molecule adjuvants. Patent number: WO2014131023 A1. Assignee: The Scripps Research Institute, The Board Of Regents Of The University Of Texas System. Priority date: 25/02/2013. Publication date: 28/08/2014. |
2. Morin MD, Wang Y, Jones BT, Su L, Surakattula MM, Berger M, Huang H, Beutler EK, Zhang H, Beutler B et al.. (2016)
Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists. J Med Chem, 59 (10): 4812-30. [PMID:27050713] |
3. Wang Y, Su L, Morin MD, Jones BT, Whitby LR, Surakattula MM, Huang H, Shi H, Choi JH, Wang KW et al.. (2016)
TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS. Proc Natl Acad Sci USA, 113 (7): E884-93. [PMID:26831104] |
4. (2011)
SECTION II: NEUROPHARMACOLOGY. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, Twelfth Edition Edited by Brunton L, Chabner B, Knollman B (McGraw-Hill Professional) 1808. [ISBN:9780071624428] |